The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.
Mitochondrial metabolism and cancer
Open accessAbstract
Glycolysis has long been considered as the major metabolic process for energy production and anabolic growth in cancer cells. Although such a view has been instrumental for the development of powerful imaging tools that are still used in the clinics, it is now clear that mitochondria play a key role in oncogenesis. Besides exerting central bioenergetic functions, mitochondria provide indeed building blocks for tumor anabolism, control redox and calcium homeostasis, participate in transcriptional regulation, and govern cell death. Thus, mitochondria constitute promising targets for the development of novel anticancer agents. However, tumors arise, progress, and respond to therapy in the context of an intimate crosstalk with the host immune system, and many immunological functions rely on intact mitochondrial metabolism. Here, we review the cancer cell-intrinsic and cell-extrinsic mechanisms through which mitochondria influence all steps of oncogenesis, with a focus on the therapeutic potential of targeting mitochondrial metabolism for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“, ATP citrate lyase (ACLY), is required for cancer cells to proliferate at optimal rates [85], but not for normal cells to do so (owing to a glucose-to-acetate metabolic switch) [86].”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Thus, it is now widely accepted that tumors form, develop and respond to therapy in the context of a complex, bidirectional interaction with the host immune system [5, 6].”
BackgroundInduction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c
Liu, X., Kim, C. N., Yang, J., Jemmerson, R., & Wang, X. (1996) · Cell · doi:10.1016/s0092-8674(00)80085-9 · Cited by 5,167
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Cited by
Flavonoids as Anticancer Agents
Kopustinskiene, D. M., Jakstas, V., Savickas, A., & Bernatoniene, J. (2020) · Nutrients · doi:10.3390/nu12020457 · Cited by 1,295
Autophagy: Regulator of cell death
Liu, S., Yao, S., Yang, H., Liu, S., & Wang, Y. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06154-8 · Cited by 1,125
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
Cuproptosis: mechanisms and links with cancers
Xie, J., Yang, Y., Gao, Y., & He, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01732-y · Cited by 801
Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances
Xu, X., Pang, Y., & Fan, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02253-4 · Cited by 800
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma
Espíndola, K. M. M., Ferreira, R. G., Narvaez, L. E. M., Silva Rosario, A. C. R., da Silva, A. H. M., Silva, A. G. B., Vieira, A. P. O., & Monteiro, M. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00541 · Cited by 610
Ferroptosis and Cancer: Mitochondria Meet the “Iron Maiden” Cell Death
Battaglia, A. M., Chirillo, R., Aversa, I., Sacco, A., Costanzo, F., & Biamonte, F. (2020) · Cells · doi:10.3390/cells9061505 · Cited by 561
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 460
Mitochondrial calcium exchange in physiology and disease
Garbincius, J. F., & Elrod, J. W. (2022) · Physiological Reviews · doi:10.1152/physrev.00041.2020 · Cited by 412
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
“mtDNA Repair Pathway Recently, the exploration of novel anticancer strategies aiming at the differences in mitochondrial function and structure between normal cells and cancer cells has received intensive attention (Porporato et al., 2018).”
BackgroundSex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
Flavonoids and their role in oxidative stress, inflammation, and human diseases
Jomova, K., Alomar, S. Y., Valko, R., Liska, J., Nepovimova, E., Kuca, K., & Valko, M. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111489 · Cited by 362
Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy
Zheng, P., Zhou, C., Lu, L., Liu, B., & Ding, Y. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02485-0 · Cited by 352
Metabolic interventions in the immune response to cancer
O’Sullivan, D., Sanin, D. E., Pearce, E. J., & Pearce, E. L. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0140-9 · Cited by 312
Cardiovascular disease and cancer: shared risk factors and mechanisms
Wilcox, N. S., Amit, U., Reibel, J. B., Berlin, E., Howell, K., & Ky, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01017-x · Cited by 310
Levoux, J., Prola, A., Lafuste, P., Gervais, M., Chevallier, N., Koumaiha, Z., Kefi, K., Braud, L., Schmitt, A., Yacia, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.006 · Cited by 290
Trial watch: STING agonists in cancer therapy
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289
Self-citationCastro-Portuguez, R., & Sutphin, G. L. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110841 · Cited by 281
Autophagy and mitophagy in cancer metabolic remodelling
Ferro, F., Servais, S., Besson, P., Roger, S., Dumas, J.-F., & Brisson, L. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.029 · Cited by 281
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 273
Mitochondria Targeting as an Effective Strategy for Cancer Therapy
Ghosh, P., Vidal, C., Dey, S., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093363 · Cited by 263
Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance
Xie, B., Wang, S., Jiang, N., & Li, J. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.11.019 · Cited by 261
The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression
Wang, H., Yung, M. M. H., Ngan, H. Y. S., Chan, K. K. L., & Chan, D. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126560 · Cited by 254
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Marchi, S., Giorgi, C., Galluzzi, L., & Pinton, P. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.017 · Cited by 235
Self-citationSmall molecules regulating reactive oxygen species homeostasis for cancer therapy
Zhang, J., Duan, D., Song, Z., Liu, T., Hou, Y., & Fang, J. (2021) · Medicinal Research Reviews · doi:10.1002/med.21734 · Cited by 184
Protein neddylation and its role in health and diseases
Zhang, S., Yu, Q., Li, Z., Zhao, Y., & Sun, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01800-9 · Cited by 171
“235 Structurally, mitochondrial organelles are highly dynamic by undergoing fusion, fi ssion, transport and degradation, which is crucial for maintaining mitochondrial functions and cellular metabolic reprogramming.”
BackgroundTumour predisposition and cancer syndromes as models to study gene–environment interactions
Carbone, M., Arron, S. T., Beutler, B., Bononi, A., Cavenee, W., Cleaver, J. E., Croce, C. M., D’Andrea, A., Foulkes, W. D., Gaudino, G., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0265-y · Cited by 147
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133
Luo, J., Wang, X., Shi, Z., Zeng, Y., He, L., Cao, J., Sun, Y., Zhang, T., & Huang, P. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01453-2 · Cited by 104
Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases
Stanga, S., Caretto, A., Boido, M., & Vercelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103719 · Cited by 90
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Little, A. C., Kovalenko, I., Goo, L. E., Hong, H. S., Kerk, S. A., Yates, J. A., Purohit, V., Lombard, D. B., Merajver, S. D., & Lyssiotis, C. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0988-z · Cited by 88
Host mitochondrial transcriptome response to SARS-CoV-2 in multiple cell models and clinical samples
Miller, B., Silverstein, A., Flores, M., Cao, K., Kumagai, H., Mehta, H. H., Yen, K., Kim, S. J., & Cohen, P. (2021) · Scientific Reports · doi:10.1038/s41598-020-79552-z · Cited by 86
Mitochondria targeted fluorogenic theranostic agents for cancer therapy
Singh, H., Sareen, D., George, J. M., Bhardwaj, V., Rha, H., Lee, S. J., Sharma, S., Sharma, A., & Kim, J. S. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214283 · Cited by 72
Lewis, J. E., Forshaw, T. E., Boothman, D. A., Furdui, C. M., & Kemp, M. L. (2021) · Cell Systems · doi:10.1016/j.cels.2020.12.001 · Cited by 61
Adlimoghaddam, A., Odero, G. G., Glazner, G., Turner, R. S., & Albensi, B. C. (2021) · Aging and disease · doi:10.14336/ad.2020.0910 · Cited by 38
SALL4: An Intriguing Therapeutic Target in Cancer Treatment
Moein, S., Tenen, D. G., Amabile, G., & Chai, L. (2022) · Cells · doi:10.3390/cells11162601 · Cited by 35
“Oligomycin is a macrolide produced by Streptomyces and an inhibitor of adenosine triphosphate (ATP) synthase [90].”
BackgroundmiR-34a-5p regulates PINK1-mediated mitophagy via multiple modes
Tai, Y., Pu, M., Yuan, L., Guo, H., Qiao, J., Lu, H., Wang, G., Chen, J., Qi, X., Tao, Z., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119415 · Cited by 33
The structure of the human LACTB filament reveals the mechanisms of assembly and membrane binding
Bennett, J. A., Steward, L. R., Rudolph, J., Voss, A. P., & Aydin, H. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001899 · Cited by 16
Metadata
- Authors
- Porporato, P. E., Filigheddu, N., Pedro, J. M. B.-S., Kroemer, G., & Galluzzi, L.
- Venue
- Cell Research
- Published
- 2017-12-08
- Volume
- 28
- Issue
- 3
- Pages
- 265-280
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- OpenAlex
- W2773927148
- Cited by
- 1,273
- References
- 226
- FWCI
- 22.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.